Robin R Hennessy1, Isaac B Weisfuse, Karen Schlanger. 1. Bureau of STD Control/Hepatitis C Program, New York City Department of Health and Mental Hygiene, New York, NY 10013, USA. rrhenness@health.nyc.gov
Abstract
OBJECTIVE: Injection drug users (IDUs) are at high risk for multiple health problems, including human immunodeficiency virus (HIV), viral hepatitis, and sexually transmitted diseases (STDs), and are likely to have poor access to health care. To more effectively serve high-risk clients, experts recommend that programs accessed by such client populations offer integrated services. In 2000, the New York City Department of Health and Mental Hygiene integrated viral hepatitis services (vaccine and screening) into a publicly funded STD clinic. We evaluated integrated service delivery to high-risk IDUs at this clinic. METHODS: Hepatitis data were reviewed to identify clients who self-reported as IDUs. STD medical records of these clients were abstracted to ascertain primary reason for clinic visit, STD/HIV services received, and diagnoses made. RESULTS: Between May 2000 and March 2004, 8,778 individuals received hepatitis services, of whom 3% (279/8,778) reported injection drug use. Nearly 60% (161/279) of IDUs reported availability of hepatitis services as the primary reason for the clinic visit. Of these 161 clients, 103 (64%) also received other services; 54% (55/103) had an STD exam (yielding 12 new STD diagnoses), and 59% (61/103) had HIV counseling and testing (yielding two new HIV cases). Of these 103 clients, 31 (30%) were referred to the clinic for hepatitis services from a drug treatment center, and 77% (24/31) tested positive for the antibody to hepatitis C virus. CONCLUSIONS: Integrated hepatitis services appeared to attract IDUs to this STD clinic, where many also benefited from STD/HIV exams, testing, treatment, and referrals they may not have received otherwise.
OBJECTIVE: Injection drug users (IDUs) are at high risk for multiple health problems, including human immunodeficiency virus (HIV), viral hepatitis, and sexually transmitted diseases (STDs), and are likely to have poor access to health care. To more effectively serve high-risk clients, experts recommend that programs accessed by such client populations offer integrated services. In 2000, the New York City Department of Health and Mental Hygiene integrated viral hepatitis services (vaccine and screening) into a publicly funded STD clinic. We evaluated integrated service delivery to high-risk IDUs at this clinic. METHODS:Hepatitis data were reviewed to identify clients who self-reported as IDUs. STD medical records of these clients were abstracted to ascertain primary reason for clinic visit, STD/HIV services received, and diagnoses made. RESULTS: Between May 2000 and March 2004, 8,778 individuals received hepatitis services, of whom 3% (279/8,778) reported injection drug use. Nearly 60% (161/279) of IDUs reported availability of hepatitis services as the primary reason for the clinic visit. Of these 161 clients, 103 (64%) also received other services; 54% (55/103) had an STD exam (yielding 12 new STD diagnoses), and 59% (61/103) had HIV counseling and testing (yielding two new HIV cases). Of these 103 clients, 31 (30%) were referred to the clinic for hepatitis services from a drug treatment center, and 77% (24/31) tested positive for the antibody to hepatitis C virus. CONCLUSIONS: Integrated hepatitis services appeared to attract IDUs to this STD clinic, where many also benefited from STD/HIV exams, testing, treatment, and referrals they may not have received otherwise.
Authors: Robert A Gunn; Paula J Murray; Carolyn H Brennan; David B Callahan; Miriam J Alter; Harold S Margolis Journal: Sex Transm Dis Date: 2003-04 Impact factor: 2.830
Authors: Robert A Gunn; Marjorie A Lee; David B Callahan; Patricia Gonzales; Paula J Murray; Harold S Margolis Journal: Am J Prev Med Date: 2005-07 Impact factor: 5.043
Authors: Jeanne Carey; David C Perlman; Patricia Friedmann; Wendy M Kaplan; Ann Nugent; Meredith Deutscher; Carmen L Masson; Don C Des Jarlais Journal: J Subst Abuse Treat Date: 2005-07
Authors: Arlene C Seña; Sarah J Willis; Alison Hilton; Alexandria Anderson; David A Wohl; Christopher B Hurt; Andrew J Muir Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Carolyn K Burr; Deborah S Storm; Mary Jo Hoyt; Loretta Dutton; Linda Berezny; Virginia Allread; Sindy Paul Journal: Public Health Rep Date: 2014 Jan-Feb Impact factor: 2.792
Authors: M A Fill; L A Sizemore; M Rickles; K C Cooper; C M Buecker; H L Mullins; M G Hofmeister; W E Abara; M A Foster; A K Asher; W Schaffner; J R Dunn; T F Jones; C Wester Journal: Epidemiol Infect Date: 2018-02-12 Impact factor: 4.434
Authors: Victoria Haldane; Francisco Cervero-Liceras; Fiona Lh Chuah; Suan Ee Ong; Georgina Murphy; Louise Sigfrid; Nicola Watt; Dina Balabanova; Sue Hogarth; Will Maimaris; Kent Buse; Peter Piot; Martin McKee; Pablo Perel; Helena Legido-Quigley Journal: J Int AIDS Soc Date: 2017-05-30 Impact factor: 5.396
Authors: Nicola Watt; Louise Sigfrid; Helena Legido-Quigley; Sue Hogarth; Will Maimaris; Laura Otero-García; Pablo Perel; Kent Buse; Martin McKee; Peter Piot; Dina Balabanova Journal: Health Policy Plan Date: 2017-11-01 Impact factor: 3.344